Shots:
- Biogen has entered into a definitive agreement to acquire RayThera, expanding its immunology pipeline
- As per the deal, Biogen will acquire RayThera for ~$1B, incl. an upfront payment & clinical and regulatory milestone payments; closing is expected in Q3’26
- Following closing, Biogen will lead development, manufacturing & global commercialization of RayThera’s assets, incl. the lead candidate expected to enter P-I development in early Q3’26
Ref: Globenewswire | Image: RayThera | Press Release
Related News: Biogen Reports P-II (CELIA) Trial Results on Diranersen in Early Alzheimer’s Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
